Plain-English translation of NCT06010472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new treatment called KN5501—specially engineered natural killer cells designed to target a specific protein involved in lupus. Researchers want to see if infusing these cells into patients with moderate to severe lupus that hasn't responded to standard medicines can safely reduce disease activity. This is one of the first human studies of this approach.
Some patients with lupus don't improve enough with current medications, leaving them with ongoing pain, organ damage, and reduced quality of life. This medication represents a new strategy—using the body's own immune cells as a tool to fight lupus—that may help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive a preparatory treatment with two chemotherapy medications (fludarabine and cyclophosphamide) to prepare your immune system, followed by an infusion of the engineered immune cells. Researchers would then monitor you closely with blood tests and disease activity assessments to track whether the treatment is safe and whether your lupus improves. The study involves about 36 patients total and will carefully watch for any side effects while measuring changes in your lupus symptoms and disease markers.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China